Search

The Spring 2023 edition of the Retina UK newsletter, Look Forward, which includes articles about our upcoming events, research updates and more.

• Look Forward
• Audio
• Written

Inflammation and retinal degeneration in retinitis pigmentosa: Can lessons learned in the lab help us identify treatments in the clinic?

• Webinar
• Video

A general overview of the clinical trials process and practicalities, including issues to consider if you are given the opportunity to take part.

• Webinar
• Video

Luxturna, a gene therapy, is only for the treatment of Leber congenital amaurosis type 2 (LCA2) and severe early-onset RP caused by mutations in a specific gene called RPE65.

• FAQ
• Written

Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.

• e-Newsletter
• Audio
• Written

Our monthly e-Newsletter featuring the latest updates from Retina UK.

• e-Newsletter
• Audio
• Written

Your generous support allows Retina UK to fund the work of leading scientists who are increasing understanding of inherited sight loss and moving us closer to treatments.

• News

As Luxturna reaches the clinic and other gene-specific therapies for inherited retinal disease get closer to the end of the development pipeline, it is becoming ever more important that affected families can access a genetic diagnosis, potentially opening up choices around treatment and clinical trial participation.

• News

Our monthly e-Newsletter featuring the latest updates from Retina UK.

• e-Newsletter
• Audio
• Written

Did you join either of our Conferences this year? You can read about them inside this edition of Look Forward. We’ve had some fantastic feedback from our delegates so if you weren’t able to attend, you can watch or listen to the recordings from the day on our website.

• Look Forward
• Audio
• Written